Sofie C. M. Tops
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sofie C. M. Tops has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
Eva Kolwijck
Department of Medical Microbiology, Jeroen Bosch Hospital, 's-Hertogenbosch, the Netherlands
4 shared publications- Heiman Frank Louis Wertheim
Radboudumc
4 shared publications - Diederik M. Somford
Department of Urology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands
2 shared publications Els de Brauwer
Department of Medical Microbiology, Zuyderland, Heerlen, The Netherlands
2 shared publications- Eva Kolwijck
Radboudumc Center for Infectious Diseases, Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, the Netherlands
2 shared publications Heiman F. L. Wertheim
Department of Medical Microbiology and Radboudumc Center for Infectious Diseases, Radboud University Medical Center , Nijmegen, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 19 May 2026
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 15 (1)
Re-evaluating microbiological testing and isolation measures for suspected MRSA carriers: insights from a retrospective study in a Dutch tertiary care center
The Netherlands has one of the lowest prevalences of methicillin-resistant Staphylococcus aureus (MRSA) in Europe due to its stringent Search and Destroy policy, including isolation of suspected carriers. Unexpected MRSA detection in non-isolated patients triggers contact tracing and screening of exposed patients and healthcare workers (HCWs). Given evolving epidemiology and healthcare practices, periodic re-evaluation of control measures is essential to sustain low prevalence while minimizing burden. This retrospective study at a Dutch tertiary hospital (2022-2024) assessed (1) diagnostic accuracy and utility of rapid MRSA PCR using Copan eSwab and Xpert MRSA NxG (Cepheid, GeneXpert); (2) proportion of unexpected MRSA among newly detected carriers; (3) transmission risk after unprotected MRSA exposure; (4) implications for optimizing screening and isolation. Data were extracted from electronic patient and laboratory records. MRSA culture and PCR results (throat, nose, rectum combined) were compared and stratified by screening indication. Among 1939 MRSA screenings, 89 (4.6%) were positive. Major screening indications were 'foreign healthcare exposure' (42.8%; 1.6% positive), 'residing in an asylum seekers' centre' (24.9%; 7.8% positive), or 'livestock contact' (14.5%; 8.6% positive). MRSA-positive household contacts had the highest MRSA test positivity (16/87; 18.4%). Compared with culture, PCR (n = 830) showed 63.9% sensitivity and 99.2% specificity, 21% of positive PCRs were false positives (7/32). Unexpected MRSA findings triggered 78 contact investigations involving 143 patients and 1550 HCWs. Nosocomial transmission occurred in 0.3% of HCWs, none in patients. Incidental MRSA was found in 0.4% of HCWs (6/1550). 30% of patients with "unexpected MRSA" lacked known risk factors; parental origin abroad was observed in 38% (exploratory analysis). "Suspected MRSA" accounted for 23% of strict isolation days. Current MRSA screening remains effective but could be optimized. Given the low transmission risk, limited PCR sensitivity, and low MRSA prevalence in high-risk groups, contact isolation instead of strict isolation may suffice while awaiting culture results in suspected carriers. A revised, risk-based approach could improve efficiency, reduce unnecessary isolation, and lower costs without compromising safety. As 30% of unexpected MRSA cases lacked established risk factors, updating screening criteria to include emerging risk factors may further strengthen detection and containment.
- 19 May 2026
- Published by Springer Nature in Antimicrobial Resistance & Infection Control
- Vol. 15 (1)
Open AccessRe-evaluating microbiological testing and isolation measures for suspected MRSA carriers: insights from a retrospective study in a Dutch tertiary care center
The Netherlands has one of the lowest prevalences of methicillin-resistant Staphylococcus aureus (MRSA) in Europe due to its stringent Search and Destroy policy, including isolation of suspected carriers. Unexpected MRSA detection in non-isolated patients triggers contact tracing and screening of exposed patients and healthcare workers (HCWs). Given evolving epidemiology and healthcare practices, periodic re-evaluation of control measures is essential to sustain low prevalence while minimizing burden. This retrospective study at a Dutch tertiary hospital (2022-2024) assessed (1) diagnostic accuracy and utility of rapid MRSA PCR using Copan eSwab and Xpert MRSA NxG (Cepheid, GeneXpert); (2) proportion of unexpected MRSA among newly detected carriers; (3) transmission risk after unprotected MRSA exposure; (4) implications for optimizing screening and isolation. Data were extracted from electronic patient and laboratory records. MRSA culture and PCR results (throat, nose, rectum combined) were compared and stratified by screening indication. Among 1939 MRSA screenings, 89 (4.6%) were positive. Major screening indications were 'foreign healthcare exposure' (42.8%; 1.6% positive), 'residing in an asylum seekers' centre' (24.9%; 7.8% positive), or 'livestock contact' (14.5%; 8.6% positive). MRSA-positive household contacts had the highest MRSA test positivity (16/87; 18.4%). Compared with culture, PCR (n = 830) showed 63.9% sensitivity and 99.2% specificity, 21% of positive PCRs were false positives (7/32). Unexpected MRSA findings triggered 78 contact investigations involving 143 patients and 1550 HCWs. Nosocomial transmission occurred in 0.3% of HCWs, none in patients. Incidental MRSA was found in 0.4% of HCWs (6/1550). 30% of patients with "unexpected MRSA" lacked known risk factors; parental origin abroad was observed in 38% (exploratory analysis). "Suspected MRSA" accounted for 23% of strict isolation days. Current MRSA screening remains effective but could be optimized. Given the low transmission risk, limited PCR sensitivity, and low MRSA prevalence in high-risk groups, contact isolation instead of strict isolation may suffice while awaiting culture results in suspected carriers. A revised, risk-based approach could improve efficiency, reduce unnecessary isolation, and lower costs without compromising safety. As 30% of unexpected MRSA cases lacked established risk factors, updating screening criteria to include emerging risk factors may further strengthen detection and containment.
- Open Access
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0311623
The diagnostic accuracy of the GeneXpert ESBL- ampC prototype assay for rapid PCR-based detection of extended-spectrum beta-lactamase genes directly from urine
The emerging prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacterales has implications for the empirical treatment of common infections, such as complicated urinary tract infections. To provide adequate treatment, while avoiding empirical therapy with last resort carbapenems, rapid identification of ESBL-containing pathogens is desirable. Routine urine samples were collected between February and July 2021 in two Dutch clinical medical microbiology laboratories according to a predefined list containing certain culture characteristics. All urine samples were screened for the presence of ESBL genes ( bla CTX-M2 , bla CTX-M14 , and bla CTX-M15 ) with random-access quantitative PCR (qPCR) using the Cepheid GeneXpert ESBL- ampC prototype assay. The qPCR and microbiological culture results were compared. After the calculation of the sensitivity and specificity, discrepancies were investigated by whole-genome sequencing. In total, 276 urine samples were available for ESBL analysis (94 ESBL culture positive and 182 ESBL culture negative). The sensitivity and specificity for detection of ESBL genes were 90.4% and 98.4%, respectively. In nine samples (9.6%), no ESBL genes were detected with GeneXpert, while in the microbiological culture, an ESBL-positive organism was isolated. This was mainly explained by non-GeneXpert ESBL genes: bla SHV -family ( n = 6; 75.0%), bla TEM -family ( n = 1; 12.5%), and bla SRT -family ( n = 1; 12.5%). The positive and negative predictive values in a hypothetical clinical scenario with a 15% ESBL prevalence were 0.91 and 0.98, respectively. Regarding ampC , the specificity appears to be satisfactory, but the sensitivity is low. The Cepheid GeneXpert ESBL assay could be beneficial for the fast and accurate detection of ESBL genes in regions where the epidemiology of ESBL genes coincides with the targets in the panel. IMPORTANCE: Early identification of complicated urinary tract infections caused by ESBL-producing Enterobacterales has the potential to limit the use of carbapenems to those patients without alternative antibiotic options and avoid the empirical use of carbapenems in patients without ESBL-producing bacteria. The purpose for such a test will differ by setting and ESBL prevalence rates. Countries with low ESBL rates and cephalosporins as empiric treatment (e.g., The Netherlands) will need a rule-in test to decide to use carbapenems, while countries with high ESBL rates and empiric carbapenem treatment will need a rule-out test for ESBLs to de-escalate therapy early. Anyway, such as a test would—at least theoretically—improve patient care and reduce selective pressure for the emergence of carbapenem resistance.
- 12 December 2023
- Published by American Society for Microbiology in Microbiology Spectrum
- Vol. 11 (6) , e0311623
Open AccessThe diagnostic accuracy of the GeneXpert ESBL- ampC prototype assay for rapid PCR-based detection of extended-spectrum beta-lactamase genes directly from urine
The emerging prevalence of extended-spectrum beta-lactamase (ESBL) producing Enterobacterales has implications for the empirical treatment of common infections, such as complicated urinary tract infections. To provide adequate treatment, while avoiding empirical therapy with last resort carbapenems, rapid identification of ESBL-containing pathogens is desirable. Routine urine samples were collected between February and July 2021 in two Dutch clinical medical microbiology laboratories according to a predefined list containing certain culture characteristics. All urine samples were screened for the presence of ESBL genes ( bla CTX-M2 , bla CTX-M14 , and bla CTX-M15 ) with random-access quantitative PCR (qPCR) using the Cepheid GeneXpert ESBL- ampC prototype assay. The qPCR and microbiological culture results were compared. After the calculation of the sensitivity and specificity, discrepancies were investigated by whole-genome sequencing. In total, 276 urine samples were available for ESBL analysis (94 ESBL culture positive and 182 ESBL culture negative). The sensitivity and specificity for detection of ESBL genes were 90.4% and 98.4%, respectively. In nine samples (9.6%), no ESBL genes were detected with GeneXpert, while in the microbiological culture, an ESBL-positive organism was isolated. This was mainly explained by non-GeneXpert ESBL genes: bla SHV -family ( n = 6; 75.0%), bla TEM -family ( n = 1; 12.5%), and bla SRT -family ( n = 1; 12.5%). The positive and negative predictive values in a hypothetical clinical scenario with a 15% ESBL prevalence were 0.91 and 0.98, respectively. Regarding ampC , the specificity appears to be satisfactory, but the sensitivity is low. The Cepheid GeneXpert ESBL assay could be beneficial for the fast and accurate detection of ESBL genes in regions where the epidemiology of ESBL genes coincides with the targets in the panel. IMPORTANCE: Early identification of complicated urinary tract infections caused by ESBL-producing Enterobacterales has the potential to limit the use of carbapenems to those patients without alternative antibiotic options and avoid the empirical use of carbapenems in patients without ESBL-producing bacteria. The purpose for such a test will differ by setting and ESBL prevalence rates. Countries with low ESBL rates and cephalosporins as empiric treatment (e.g., The Netherlands) will need a rule-in test to decide to use carbapenems, while countries with high ESBL rates and empiric carbapenem treatment will need a rule-out test for ESBLs to de-escalate therapy early. Anyway, such as a test would—at least theoretically—improve patient care and reduce selective pressure for the emergence of carbapenem resistance.
- Open Access
- 26 February 2023
- Published by Elsevier in European Urology Open Science
- Vol. 50, 70-77
Cost Effectiveness of Rectal Culture-based Antibiotic Prophylaxis in Transrectal Prostate Biopsy: The Results from a Randomized, Nonblinded, Multicenter Trial
- 26 February 2023
- Published by Elsevier in European Urology Open Science
- Vol. 50, 70-77
Open AccessCost Effectiveness of Rectal Culture-based Antibiotic Prophylaxis in Transrectal Prostate Biopsy: The Results from a Randomized, Nonblinded, Multicenter Trial
- Open Access
- 24 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (7) , 1188-1196
Rectal Culture-Based Versus Empirical Antibiotic Prophylaxis to Prevent Infectious Complications in Men Undergoing Transrectal Prostate Biopsy: A Randomized, Nonblinded Multicenter Trial
An increase in infections after transrectal prostate biopsy (PB), related to an increasing number of patients with ciprofloxacin-resistant rectal flora, necessitates the exploration of alternatives for the traditionally used empirical prophylaxis of ciprofloxacin. We compared infectious complication rates after transrectal PB using empirical ciprofloxacin prophylaxis versus culture-based prophylaxis. In this nonblinded, randomized trial, between 4 April 2018 and 30 July 2021, we enrolled 1538 patients from 11 Dutch hospitals undergoing transrectal PB. After rectal swab collection, patients were randomized 1:1 to receive empirical prophylaxis with oral ciprofloxacin (control group [CG]) or culture-based prophylaxis (intervention group [IG]). Primary outcome was any infectious complication within 7 days after biopsy. Secondary outcomes were infectious complications within 30 days, and bacteremia and bacteriuria within 7 and 30 days postbiopsy. For primary outcome analysis, the χ2 test stratified for hospitals was used. Trial registration number: NCT03228108. Data from 1288 patients (83.7%) were available for analysis (CG, 652; IG, 636). Infection rates within 7 days postbiopsy were 4.3% (n = 28) (CG) and 2.5% (n = 16) (IG) (P value = .08; reduction: −1.8%; 95% confidence interval, −.004 to .040). Ciprofloxacin-resistant bacteria were detected in 15.2% (n = 1288). In the CG, the presence of ciprofloxacin-resistant rectal flora resulted in a 6.2-fold higher risk of early postbiopsy infection. Our study supports the use of culture-based prophylaxis to reduce infectious complications after transrectal PB. Despite adequate prophylaxis, postbiopsy infections can still occur. Therefore, culture-based prophylaxis must be weighed against other strategies that could reduce postbiopsy infections. Clinical Trials Registration. NCT03228108.
- 24 November 2022
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 76 (7) , 1188-1196
Open AccessRectal Culture-Based Versus Empirical Antibiotic Prophylaxis to Prevent Infectious Complications in Men Undergoing Transrectal Prostate Biopsy: A Randomized, Nonblinded Multicenter Trial
An increase in infections after transrectal prostate biopsy (PB), related to an increasing number of patients with ciprofloxacin-resistant rectal flora, necessitates the exploration of alternatives for the traditionally used empirical prophylaxis of ciprofloxacin. We compared infectious complication rates after transrectal PB using empirical ciprofloxacin prophylaxis versus culture-based prophylaxis. In this nonblinded, randomized trial, between 4 April 2018 and 30 July 2021, we enrolled 1538 patients from 11 Dutch hospitals undergoing transrectal PB. After rectal swab collection, patients were randomized 1:1 to receive empirical prophylaxis with oral ciprofloxacin (control group [CG]) or culture-based prophylaxis (intervention group [IG]). Primary outcome was any infectious complication within 7 days after biopsy. Secondary outcomes were infectious complications within 30 days, and bacteremia and bacteriuria within 7 and 30 days postbiopsy. For primary outcome analysis, the χ2 test stratified for hospitals was used. Trial registration number: NCT03228108. Data from 1288 patients (83.7%) were available for analysis (CG, 652; IG, 636). Infection rates within 7 days postbiopsy were 4.3% (n = 28) (CG) and 2.5% (n = 16) (IG) (P value = .08; reduction: −1.8%; 95% confidence interval, −.004 to .040). Ciprofloxacin-resistant bacteria were detected in 15.2% (n = 1288). In the CG, the presence of ciprofloxacin-resistant rectal flora resulted in a 6.2-fold higher risk of early postbiopsy infection. Our study supports the use of culture-based prophylaxis to reduce infectious complications after transrectal PB. Despite adequate prophylaxis, postbiopsy infections can still occur. Therefore, culture-based prophylaxis must be weighed against other strategies that could reduce postbiopsy infections. Clinical Trials Registration. NCT03228108.
- Open Access
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (1) , 109-118
The Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications
Purpose:To compare infectious complication rates between different prostate biopsy techniques with various number of biopsy cores.Materials and Methods:In this retrospective study, all patients fro...
- 1 July 2022
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 208 (1) , 109-118
Open AccessThe Effect of Different Types of Prostate Biopsy Techniques on Post-Biopsy Infectious Complications
Purpose:To compare infectious complication rates between different prostate biopsy techniques with various number of biopsy cores.Materials and Methods:In this retrospective study, all patients fro...
- Open Access
- 17 November 2021
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 3 (4) , dlab161
Acceptability of innovative culture-based antibiotic prophylaxis strategies: a multi-method study on experiences regarding transrectal prostate biopsy
The acceptability of innovative medical strategies among healthcare providers and patients affects their uptake in daily clinical practice. To explore experiences of healthcare providers and patients with culture-based antibiotic prophylaxis in transrectal prostate biopsy with three swab-screening scenarios: self-sampling at home, self-sampling in the hospital and sampling by a healthcare provider. We performed focus group interviews with urologists and medical microbiologists from 11 hospitals and six connected clinical microbiological laboratories. We used Flottorp’s comprehensive checklist for identifying determinants of practice to guide data collection and analysis. The experiences of 10 laboratory technicians from five laboratories and 452 patients from nine hospitals were assessed using a questionnaire. Overall, culture-based prophylaxis strategies were experienced as feasible in daily clinical practice. None of the three swab-screening scenarios performed better. For urologists (n = 5), implementation depended on the effectiveness of the strategy. In addition, it was important to them that the speed of existing oncology care pathways is preserved. Medical microbiologists (n = 5) and laboratory technicians (n = 8) expected the strategy to be fairly easy to implement. Patients (n = 430; response rate 95.1%) were generally satisfied with the screening scenario presented to them. To meet the various patients’ needs and preferences, multiple scenarios within a hospital are probably needed. This multi-method study has increased our understanding of the acceptability of culture-based prophylaxis strategies in prostate biopsy, which can help healthcare providers to offer high-quality patient-centred care. The strategy seems relatively straightforward to implement as overall acceptance appears to be high.
- 17 November 2021
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 3 (4) , dlab161
Open AccessAcceptability of innovative culture-based antibiotic prophylaxis strategies: a multi-method study on experiences regarding transrectal prostate biopsy
The acceptability of innovative medical strategies among healthcare providers and patients affects their uptake in daily clinical practice. To explore experiences of healthcare providers and patients with culture-based antibiotic prophylaxis in transrectal prostate biopsy with three swab-screening scenarios: self-sampling at home, self-sampling in the hospital and sampling by a healthcare provider. We performed focus group interviews with urologists and medical microbiologists from 11 hospitals and six connected clinical microbiological laboratories. We used Flottorp’s comprehensive checklist for identifying determinants of practice to guide data collection and analysis. The experiences of 10 laboratory technicians from five laboratories and 452 patients from nine hospitals were assessed using a questionnaire. Overall, culture-based prophylaxis strategies were experienced as feasible in daily clinical practice. None of the three swab-screening scenarios performed better. For urologists (n = 5), implementation depended on the effectiveness of the strategy. In addition, it was important to them that the speed of existing oncology care pathways is preserved. Medical microbiologists (n = 5) and laboratory technicians (n = 8) expected the strategy to be fairly easy to implement. Patients (n = 430; response rate 95.1%) were generally satisfied with the screening scenario presented to them. To meet the various patients’ needs and preferences, multiple scenarios within a hospital are probably needed. This multi-method study has increased our understanding of the acceptability of culture-based prophylaxis strategies in prostate biopsy, which can help healthcare providers to offer high-quality patient-centred care. The strategy seems relatively straightforward to implement as overall acceptance appears to be high.
- Open Access
- 1 September 2020
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 98 (1) , 115100
Recovery of aerobic gram-negative bacteria from the Copan Eswab transport system after long-term storage
- 1 September 2020
- Published by Elsevier in Diagnostic Microbiology and Infectious Disease
- Vol. 98 (1) , 115100
Open AccessRecovery of aerobic gram-negative bacteria from the Copan Eswab transport system after long-term storage
- Open Access
- 12 March 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-9
Prostate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands
Background: The clinical landscape of prostate biopsy (PB) is evolving with changes in procedures and techniques. Moreover, antibiotic resistance is increasing and influences the efficacy of pre-biopsy prophylactic regimens. Therefore, increasing antibiotic resistance may impact on clinical care, which probably results in differences between hospitals. The objective of our study is to determine the (variability in) current practices of PB in the Netherlands and to gain insight into Dutch urologists’ perceptions of fluoroquinolone resistance and biopsy related infections.Methods: An online questionnaire was prepared using SurveyMonkey® platform and distributed to all 420 members of the Dutch Association of Urology, who work in 81 Dutch hospitals. Information about PB techniques and periprocedural antimicrobial prophylaxis was collected. Urologists’ perceptions regarding pre-biopsy antibiotic prophylaxis in an era of antibiotic resistance was assessed. Descriptive statistical analysis was performed.Results: One hundred sixty-one responses (38.3%) were analyzed representing 65 (80.3%) of all Dutch hospitals performing PB. Transrectal ultrasound guided prostate biopsy (TRUSPB) was performed in 64 (98.5%) hospitals. 43.1% of the hospitals (also) used other image-guided biopsy techniques. Twenty-three different empirical prophylactic regimens were reported among the hospitals. Ciprofloxacin was most commonly prescribed (84.4%). The duration ranged from one pre-biopsy dose (59.4%) to 5 days extended prophylaxis. 25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.Conclusions: There is a wide variation in practice patterns among Dutch urologists. TRUSPB is the most commonly used biopsy technique, but other image-guided biopsy techniques are increasingly used. Antimicrobial prophylaxis is not standardized and prolonged prophylaxis is common. The wide variation in practice patterns and lack of standardization underlines the need for evidence-based recommendations to guide urologists in choosing appropriate antimicrobial prophylaxis for PB in the context of increasing antibiotic resistance.
- 12 March 2020
- Published by Springer Nature in BMC Urology
- Vol. 20 (1) , 1-9
Open AccessProstate biopsy techniques and pre-biopsy prophylactic measures: variation in current practice patterns in the Netherlands
Background: The clinical landscape of prostate biopsy (PB) is evolving with changes in procedures and techniques. Moreover, antibiotic resistance is increasing and influences the efficacy of pre-biopsy prophylactic regimens. Therefore, increasing antibiotic resistance may impact on clinical care, which probably results in differences between hospitals. The objective of our study is to determine the (variability in) current practices of PB in the Netherlands and to gain insight into Dutch urologists’ perceptions of fluoroquinolone resistance and biopsy related infections.Methods: An online questionnaire was prepared using SurveyMonkey® platform and distributed to all 420 members of the Dutch Association of Urology, who work in 81 Dutch hospitals. Information about PB techniques and periprocedural antimicrobial prophylaxis was collected. Urologists’ perceptions regarding pre-biopsy antibiotic prophylaxis in an era of antibiotic resistance was assessed. Descriptive statistical analysis was performed.Results: One hundred sixty-one responses (38.3%) were analyzed representing 65 (80.3%) of all Dutch hospitals performing PB. Transrectal ultrasound guided prostate biopsy (TRUSPB) was performed in 64 (98.5%) hospitals. 43.1% of the hospitals (also) used other image-guided biopsy techniques. Twenty-three different empirical prophylactic regimens were reported among the hospitals. Ciprofloxacin was most commonly prescribed (84.4%). The duration ranged from one pre-biopsy dose (59.4%) to 5 days extended prophylaxis. 25.2% of the urologists experienced ciprofloxacin resistance as a current problem in the prevention of biopsy related infections and 73.6% as a future problem.Conclusions: There is a wide variation in practice patterns among Dutch urologists. TRUSPB is the most commonly used biopsy technique, but other image-guided biopsy techniques are increasingly used. Antimicrobial prophylaxis is not standardized and prolonged prophylaxis is common. The wide variation in practice patterns and lack of standardization underlines the need for evidence-based recommendations to guide urologists in choosing appropriate antimicrobial prophylaxis for PB in the context of increasing antibiotic resistance.
- 1 September 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (9) , e00253-18
Performance Validation of Selective Screening Agars for Guiding Antimicrobial Prophylaxis in Patients Undergoing Prostate Biopsy
A rectal culture-guided antimicrobial prophylaxis strategy may prevent infections after transrectal ultrasound-guided prostate biopsy (TRUSP). The use of selective culture media could assist the choice of appropriate antibiotic prophylaxis. The objective of our study was to evaluate the performance of four selective media used for guidance of oral antibiotic prophylaxis in TRUSP. In this prospective validation study, we used MacConkey media with vancomycin plus one of the following antibiotics: ciprofloxacin (McC3+CIP/V), trimethoprim (McC3+TMP/V), fosfomycin (McC3+FOF/V), and amdinocillin-amoxicillin-clavulanic acid (McC3+MEC/V). First, clinical strains of Gram-negative bacilli (GNB) (n = 33) were evaluated for growth on the selective media. Thereafter, rectal swabs (n = 97) were randomly collected from residual material of fresh stool samples and plated on a growth control and the four selective media. Levels of recovery of GNB on the growth control and selective media were compared, and the MICs of the antibiotics used in this study were determined. The sensitivity and specificity of the four selective media amounted, respectively, to 90.0% (55.5 to 99.8%) and 98.7% (93.1 to 100.0%) for McC3+CIP/V, 95.7% (85.2 to 99.5%) and 100.0% (91.6 to 100.0%) for McC3+TMP/V, 95.5% (84.5 to 99.4%) and 97.8% (88.2 to 99.9%) for McC3+FOF/V, and 100.0% (76.8 to 100.0%) and 97.6% (87.4 to 99.9%) for McC3+MEC/V. In conclusion, the four selective media were sufficiently sensitive and specific for the identification of rectal GNB resistant to ciprofloxacin, trimethoprim, fosfomycin, or amdinocillin-amoxicillin-clavulanic acid. These media can have added value in streamlining the optimal culture based antibiotic prophylaxis in TRUSP in a non-labor-intensive manner.
- 1 September 2018
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 56 (9) , e00253-18
Performance Validation of Selective Screening Agars for Guiding Antimicrobial Prophylaxis in Patients Undergoing Prostate Biopsy
A rectal culture-guided antimicrobial prophylaxis strategy may prevent infections after transrectal ultrasound-guided prostate biopsy (TRUSP). The use of selective culture media could assist the choice of appropriate antibiotic prophylaxis. The objective of our study was to evaluate the performance of four selective media used for guidance of oral antibiotic prophylaxis in TRUSP. In this prospective validation study, we used MacConkey media with vancomycin plus one of the following antibiotics: ciprofloxacin (McC3+CIP/V), trimethoprim (McC3+TMP/V), fosfomycin (McC3+FOF/V), and amdinocillin-amoxicillin-clavulanic acid (McC3+MEC/V). First, clinical strains of Gram-negative bacilli (GNB) (n = 33) were evaluated for growth on the selective media. Thereafter, rectal swabs (n = 97) were randomly collected from residual material of fresh stool samples and plated on a growth control and the four selective media. Levels of recovery of GNB on the growth control and selective media were compared, and the MICs of the antibiotics used in this study were determined. The sensitivity and specificity of the four selective media amounted, respectively, to 90.0% (55.5 to 99.8%) and 98.7% (93.1 to 100.0%) for McC3+CIP/V, 95.7% (85.2 to 99.5%) and 100.0% (91.6 to 100.0%) for McC3+TMP/V, 95.5% (84.5 to 99.4%) and 97.8% (88.2 to 99.9%) for McC3+FOF/V, and 100.0% (76.8 to 100.0%) and 97.6% (87.4 to 99.9%) for McC3+MEC/V. In conclusion, the four selective media were sufficiently sensitive and specific for the identification of rectal GNB resistant to ciprofloxacin, trimethoprim, fosfomycin, or amdinocillin-amoxicillin-clavulanic acid. These media can have added value in streamlining the optimal culture based antibiotic prophylaxis in TRUSP in a non-labor-intensive manner.
- 1 January 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (1) , e1-e2
Kidney Weight in Living and Postmortal Kidney Donation
- 1 January 2016
- Published by Wolters Kluwer Health in Transplantation
- Vol. 100 (1) , e1-e2
Kidney Weight in Living and Postmortal Kidney Donation